At least 50% of maximum pain relief over 4 to 6 hours · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Number of women requiring rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Number of women requiring rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Mean change in average muscle score: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
4‐stair climbing time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Weight gain · patients with Duchenne muscular dystrophy
1 finding from 1 review
Behavioural changes ‐ prednisone (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
Corticosteroids showed no clear difference in behavioural changes ‐ prednisone (0.75 mg/kg/day) compared with placebo (moderate certainty).
1 finding from 1 review
Mortality from any cause (tibolone 2.5 mg/d) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes mortality from any cause (tibolone 2.5 mg/d) compared with combined HT (very low certainty).
1 finding from 1 review
Vasomotor symptoms (tibolone 2.5 mg/d) · postmenopausal women with vasomotor symptoms
Tibolone probably leads to higher vasomotor symptoms (tibolone 2.5 mg/d) compared with combined HT (moderate certainty).
1 finding from 1 review
Pain‐free response at 2 h for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Pain‐free response at 2 h for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Headache relief at 2 h for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Sustained pain‐free during the 24 h post dose for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate